Danish General Practitioners' Use of Prostate-Specific Antigen in Opportunistic Screening for Prostate Cancer: A Survey Comprising 174 GPs

Table 4

Subtables comparing the GPs responses to whether they would measure PSA and their rationale behind PSA indication for symptomatic patients.

GPs responses to the corresponding questions regarding their rationale behind the PSA indication.	PSA indication*, n (%)			𝑃 value
	Yes	No	Do not know
Case D
Patients with LUTS should have measured PSA.
Yes	88 (94.6)	0 (0.0)	0 (0.0)	0.064
No	4 (4.3)	1 (100.0)	0 (0.0)
Do not know	1 (1.1)	0 (0.0)	0 (0.0)
The patient should have measured PSA, due to a family history of PC.
Yes	73 (79.3)	0 (0.0)	0 (0.0)	0.215
No	10 (10.9)	1 (100.0)	0 (0.0)
Do not know	9 (9.8)	0 (0.0)	0 (0.0)
Case E
Patients with LUTS and lower back pain should have measured PSA.
Yes	89 (98.9)	0 (0.0)	0 (0.0)	<0.001
No	0 (0.0)	1 (100.0)	1 (25.0)
Do not know	1 (1.1)	0 (0.0)	3 (75.0)
A PSA should only be measured if the prostate is palpated enlarged, hard, and knobbly.
Yes	6 (6.9)	2 (100)	1 (25.0)	<0.001
No	77 (88.5)	0 (0.0)	1 (25.0)
Do not know	4 (4.6)	0 (0.0)	2 (50.0)

∗The proportion of missing data was between 3.1% and 5.1%.